Core Insights - Tempus AI Inc. is a leader in AI-driven precision medicine, focusing on integrating AI technologies into healthcare to enhance patient outcomes [1] - The company collaborates with major pharmaceutical firms to improve the discovery and development of precision medicine biomarkers [1] Company Developments - On March 10, 2026, H.C. Wainwright set a price target of $95 for Tempus, indicating a potential increase of approximately 82.6% from its trading price of $52.03 [2] - Tempus has entered a strategic collaboration with Merck & Co. Inc. to advance AI-driven precision medicine, utilizing its advanced Lens Platform and significant GPU infrastructure for complex analyses [3] - This partnership aims to enhance Merck's oncology and broader therapeutic portfolios by identifying novel precision biomarkers and mechanisms of cancer cell resistance [4] Market Performance - Tempus' market capitalization is approximately $8.96 billion, with a trading volume of around 928,414 shares on NASDAQ [5] - The stock has fluctuated between a high of $104.32 and a low of $36.22 over the past year, despite recent declines coinciding with broader market sell-offs [4][5]

Group 1: Strategic Collaboration - Tempus AI Inc. has entered a strategic collaboration agreement with Merck & Co. to accelerate AI-driven precision medicine [1] - The partnership will utilize Tempus' extensive library of de-identified multimodal data and its advanced Lens Platform for complex analyses [2] - This collaboration aims to enhance the discovery and development of precision medicine biomarkers, particularly in oncology [2] Group 2: Financial Performance - In February, Tempus reported quarterly losses of four cents per share, aligning with consensus estimates [3] - Quarterly revenue reached $367.21 million, surpassing the Street estimate of $362.29 million and increasing from $200.68 million in the previous year [3] Group 3: Market Context - The broader market experienced a downturn, with the S&P 500 falling by 1.78% and the Nasdaq declining by 2.18%, contributing to downward pressure on Tempus shares [4] - Tempus shares are currently trading 9.8% below their 100-day simple moving average, indicating potential weakness in the longer-term trend [5] Group 4: Technical Analysis - The Relative Strength Index (RSI) is at 44.45, indicating neutral territory, while the MACD is at 0.15, below its signal line, suggesting bearish pressure [6] - The combination of neutral RSI and bearish MACD indicates mixed momentum, warranting attention for potential shifts in market sentiment [6] Group 5: Analyst Consensus - The stock carries a Buy Rating with an average price target of $74.31, with recent analyst actions reflecting varied target adjustments [7] - Tempus AI shares were down 1.56% at $52.48 at the time of publication, with key resistance at $54.00 and key support at $48.00 [7]

Core Insights - Tempus AI, Inc. and Merck have announced an expanded multi-year collaboration to enhance the discovery and development of precision medicine biomarkers, particularly in oncology [1][2] - The partnership aims to leverage Tempus' de-identified multimodal datasets and advanced AI capabilities to improve patient outcomes and accelerate the development of candidate therapies [2][3] Company Overview - Tempus is a technology company focused on advancing precision medicine through AI applications in healthcare, boasting one of the largest libraries of multimodal data [4] - The company provides AI-enabled solutions to physicians, aiming to personalize patient care and facilitate the discovery and development of optimal therapeutics [4] Collaboration Details - Under the agreement, Merck will utilize Tempus' Lens Platform and Workspaces environment, which is powered by a significant GPU infrastructure, to conduct complex analyses on multimodal datasets [2] - The collaboration is expected to enhance Merck's precision oncology strategy by applying AI/ML capabilities to discover novel biomarkers and inform drug combinations in their early pipeline [3]

Company Overview - Tempus aims to unlock precision medicine through AI-enabled diagnostics[6] - The company's platform connects to over 5,000 providers across the US[10] - Tempus leverages a large proprietary healthcare dataset of over 45 million patient records[13] Diagnostics Business - The Diagnostics business delivered approximately 800,000 clinical tests in 2025[30] - The Diagnostics business experienced a unit growth rate of approximately 28% in Q4 2025[30] - Oncology ASP is expected to rise by over $500 in the next several years due to reimbursement tailwinds[31] Data & Applications Business - Data and Applications revenue reached approximately $316 million in 2025, representing approximately 31% growth[38] - The Data & Applications business has signed over $2 billion in contracts to date[38] - The Total Remaining Contract Value (TCV) for Data & Applications is over $1.1 billion as of year-end 2025[39] - The Data Licensing Retention rate is approximately 126% as of year-end 2025[39] Financial Outlook - The company anticipates revenue of approximately $1.27 billion for 2025, reflecting approximately 83% year-over-year growth[63] - The company projects revenue growth of approximately 25% year-over-year in 2026, reaching approximately $1.59 billion[65]